Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Pixium Vision – executive interview

Pixium Vision – executive interview

Pixium Vision — 2 videos in collection

More on this equity

Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for patients with geographic atrophy related to dry-AMD. The company started the PRIMAvera European pivotal study in late 2020, and top-line data are anticipated in early 2023.

In this interview, chief executive officer Lloyd Diamond and chief financial officer Offer Nonhoff discuss how Prima differentiates itself from earlier-generation retinal implants, and provide details on the ongoing PRIMAvera study as well as the planned commercial strategy for the US and key European markets. They also review the company’s financial position and objectives, and comment on longer-term development opportunities. Finally, the company’s executives highlight some of the key catalysts and milestones expected over the next year.

< Previous
Next >

You may also be interested in these:

Healthcare

Pixium Vision – Edison Open House interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free